Towards Universal Screening for Toxoplasmosis: Rapid, Cost-Effective, and Simultaneous Detection of Anti-Toxoplasma IgG, IgM, and IgA Antibodies by Use of Very Small Serum Volumes

Swinburne A. J. Augustine
National Exposure Research Laboratory, Exposure Methods and Measurement Division, Microbial Exposure Branch, United States Environmental Protection Agency, Cincinnati, Ohio, USA


*Toxoplasma gondii* is a protozoan parasite that is infectious to all warm-blooded terrestrial and marine animals (1). Infection can be acquired congenitally (2, 3), by ingesting viable cysts in undercooked meat (4, 5), or by inhalation or ingestion of oocyst-contaminated soil or water (6, 7). Although *T. gondii* infection is largely asymptomatic in healthy humans, congenital toxoplasmosis can be devastating, leading to encephalomyelitis, convulsive seizures, respiratory problems, and fetal or infant death (2).

Because of the grave effects of congenital toxoplasmosis, it is very important to accurately and expeditiously identify pregnancy-related *Toxoplasma* infections. However, the idea of universal screening for toxoplasmosis is very controversial for a variety of reasons, including the low prevalence of infection in certain countries and the reliability of diagnostic tests. Universal screening is mandatory in certain countries, such as Austria and France, while Canada and Brazil conduct routine maternal screening to identify and assist seronegative women with preventive measures, as well as to institute early treatment of infections acquired during pregnancy (3, 8–11). Conversely, universal screening is not routinely performed and, in fact, has been discouraged in countries where the prevalence of the disease is very low, such as the United Kingdom, Norway, and the United States (3, 7, 12).

Definitive diagnostic tests for *T. gondii* infection include the gold-standard Sabin-Feldman dye test, determination of serum antibodies by enzyme-linked immunosorbent assay (ELISA), modified agglutination test, PCR, and a more recently commercially available multiplex immunoaassay, the BioPlex 2200 system (13–17). Despite the availability of these tests, universal screening remains elusive. There is some speculation that the Sabin-Feldman dye test may be cost prohibitive and too labor-intensive to set up, while many of the commercial tests that compare their results to the Sabin-Feldman dye test have been reported to have difficulty reaching 100% correlation, as well as the potential for slower detection of infection. In particular, there is currently no reference diagnostic test available for assessing IgM and IgA anti-*Toxoplasma* antibodies. Given these limitations, Xiaoyang Li and colleagues have developed and described, in this edition of the *Journal of Clinical Microbiology*, a plasmonic golden chip multiplex immunoaassay capable of simultaneously measuring IgG, IgM, and IgA antibodies against *Toxoplasma* with high sensitivity, specificity, positive predictive value, and negative predictive value in as little as 5 μl of patient serum (18).

The simultaneous detection of all three immunoglobulin isotypes, IgG, IgM, and IgA, should offer a more complete picture of the infection status of the patient. Together, these three antibody isotypes could provide information regarding seroconversion and whether the infection is acute, chronic, or reactivated. With the exception of the BioPlex 2200 (which does not measure IgA), all currently available tests would have to be run individually, thus requiring significantly larger serum sample volumes (5 to 50 μl for plasmonic gold chip- and bead-based assays versus ≥100 μl for ELISA and other assays) and an increase in reagents and labor. One solution to this problem would be to perform these assays in a multiplex format where the three antibody isotypes are measured simultaneously by using a much smaller sample volume than traditional methods. The utility and benefits of multiplex immunoaassays have been widely published. There are multiple reports of serological multiplex immunoaassays for the measurement of antibodies to a wide range of pathogens, including *T. gondii*, *Escherichia coli* O157:H7, *Helicobacter pylori*, HIV, and noroviruses (19–21). However, multiplex immunoaassays also present challenges and limitations that include cross-reactivity and assay sensitivity and specificity that must be addressed before they can be used as definitive diagnostic tools (22).

Major hurdles confronting the development of antibody screening tools include the use of invasive procedures, the need for trained personnel, and the costs involved in blood collection. To...
overcome these hurdles, research laboratories have been studying the
efficacy of replacing serum with saliva as the diagnostic fluid of
choice for measuring immune responses to pathogen exposure.
Saliva collection is noninvasive and easy to perform and requires
minimal training. Moreover, saliva has been shown to be an ideal
matrix for exposure and infection studies, as demonstrated by the
numerous reports of very good correlation of antibody responses
in paired serum and saliva samples (23–26). The combination of
speed and the ability of multiplex immunoassays to measure mul-
tiple analytes simultaneously in very small sample volumes with
the use of an easily collected noninvasive matrix like saliva may
potentially have a significant positive impact on the ability to pro-
vide universal screening for not only T. gondii infection but also
for a host of other infections.

In summary, the application of multiplex immunoassay tech-
nologies such as the plasmonic gold chip assay along with less
invasive sample collection procedures for the measurement of an-
tibodies against T. gondii and other infectious microorganisms
may provide more sensitive and specific tools to better implement
routine screening for various infections and autoimmune disor-
ders.

ACKNOWLEDGMENTS
The United States Environmental Protection Agency, through its Office
of Research and Development, funds and manages the research conducted
by S.A.I.A. The manuscript has been submitted to the agency’s adminis-
trative review and approved for publication. Mention of trade names or
commercial products does not constitute endorsement or recommenda-
tion for use.

FUNDING INFORMATION
This work, including the efforts of Swinburne A. J. Augustine, was funded
by USEPA.

The author’s research is funded by the Office of Research and Devel-
lopment, U.S. Environmental Protection Agency.

REFERENCES
1. Dubey JP. 2008. The history of Toxoplasma gondii—the first 100 years. J
2. Wolf A, Cowen D, Paige B. 1939. Human toxoplasmosis: occurrence in
    infants as anencephalomyelitis verification by transmission to animals. Science.
    org/10.1097/00006254-200105000-00025.
    87:211–216.
    1965. Epidemiological study on toxoplasmosis: the influence of cooking
    slaughter-animal meat on the incidence of human infection. Rev Fr Etud
    Clin Microbiol 10:952–958. (In French.)
    http://dx.doi.org/10.1056/NEJM197902230301302.
7. Cook AJ, Gilbert RE, Buffolano W, Zufferey J, Petersen E, Jenum PA,
    Foulon W, Semprini AE, Dunn DT. 2000. Sources of toxoplasma infec-
    tion in pregnant women: European multicentre case-control study. Euro-
    known about the prevention of congenital toxoplasmosis? Lancet 336:
    359–361.
    toxoplasmosis. J Midwifery Womens Health 48:308–316; quiz 386. http:
    //dx.doi.org/10.1016/S1526-9526(03)00027-9.
10. Pasquet C, Yudin MH, Society of Obstetricians and Gynaecologists of
    Canada. 2013. Toxoplasmosis in pregnancy: prevention, screening, and
    /J.OGCM.2013.01.003.
    of toxoplasmosis in pregnant women and vertical transmission of Toxo-
    plasma gondii in patients from basic units of health from Gurupi, To-
    org/10.1371/journal.pone.0141700.
    immunity phenomenon affecting a protozoan parasite (Toxoplasma). Science.
    toxoplasmosis II. Prevalence and significance in acquired cases. J Lab Clin
    sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by poly-
17. Guigue N, Menotti J, Hamane S, Derouin F, Garin YJ. 2014. Perfor-
    mance of the BioPlex 2200 flow immunoassay in critical cases of serodi-
    H, 2016. Multiplexed anti-Toxoplasma IgG, IgM, and IgA assay on plas-
    monic gold chips: towards making mass screening possible with dye test
    05715-15.
    Kumar A, Lappalainen M, Soderlund-Venermo M, Blomberg J, Hed-
    man K. 2016. Microsphere-based antibody assays for human parvovirus
20. Augustine SA, Simmons KJ, Eason TN, Griffin SM, Curioso CL, Wymer
    LJ, Fout GS, Grimm AC, Oshima KH, Dufour A. 2015. Statistical
    approaches to developing a multiplex immunoassay for determining hu-
    man exposure to environmental pathogens. J Immunol Methods 425:3–
    http://dx.doi.org/10.1016/j.jim.2015.06.002.
    of a multiplex microsphere immunoassay for the quantitation of salivary
    antibody responses to selected waterborne pathogens. J Immunol
    protein multiplex platforms: technical and operational challenges. Clin
    salivary protein profiling for patients with respiratory diseases using fiber-
    optic bundles and fluorescent antibody-based microarrays. Anal Chem
    spinal fluid: an epidemiological tool for investigation of waterborne disease.
    booster salivary antibody responses to a 7-valent pneumococcal conjugate
    org/10.1086/313834.
    saliva as an alternative to plasma for the detection of hepatitis C virus